Drug Pipeline News

Subgroup data show crinecerfont helps children with CAH reduce steroid use while maintaining or improving androstenedione levels across diverse patient groups.

NEC is a life-threatening condition marked by the death of intestinal tissue, which impacts preterm infants.

Prescriptions for the epinephrine nasal spray are now available for patients aged 4 years and up who weigh 33 to < 66 lbs.

Nirsevimab significantly reduces RSV-related hospitalizations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from April 2025.

Stealth BioTherapeutics' CEO stated, "We hope to gain more information on the revised action date in the coming days."

The human FcRn-blocking monoclonal antibody is indicated for gMG patients aged 12 years and older.

The decision makes pz-cel the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.

In addition, data presented at PAS revealed a predictable pharmacokinetic profile in the newborn population, consistent with adult humans.

From the FDA approvals of dupilumab and maralixibat tablets to a new puzzler case study, get caught up with our weekly review article.

The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns.

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.

Diazepam nasal spray (Valtoco) is approved for short-term treatment of seizure clusters, now in patients aged 2 years and older.

In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations.

“Data from the Phase 3 ICONIC LEAD subgroup analysis demonstrate impressive efficacy rates, showing the promise of this novel therapeutic option," said Lawrence Eichenfield, MD.

The federal agency greenlit nivolumab with ipilimumab for treating MSI-H/dMMR colorectal cancer in adults and children 12 years and up.

If approved, the expanded indication would include children and adolescents aged 6 to 17 years who weigh 99 lbs (45 kg) or more.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Aquestive Therapeutics reports positive pediatric study results for Anaphylm, supporting its FDA submission for treating severe allergic reactions.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from March 2025.

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase.

A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions to small amounts of common food allergens.

Diazoxide choline has been granted breakthrough, fast track, and orphan drug designations in the United States.

In this Q+A interview, Craig McDonald, MD, discusses the interim, 90-day data from the phase 1/2 INSPIRE DUCHENNE trial, evaluating SGT-003, a gene therapy candidate for DMD.

The approval marks a vital step toward care for urinary tract infections, helping to reduce recurrence and improve patients’ quality of life.

Results were from the phase 3 STEER study among a broad population of patients with SMA aged 2 to under 18 years.